![Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-013-0063-y/MediaObjects/12325_2013_63_Fig3_HTML.gif)
Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink
![Erythropoietin and erythropoiesis stimulating agents - Debeljak - 2012 - Drug Testing and Analysis - Wiley Online Library Erythropoietin and erythropoiesis stimulating agents - Debeljak - 2012 - Drug Testing and Analysis - Wiley Online Library](https://analyticalsciencejournals.onlinelibrary.wiley.com/cms/asset/6b4b1317-92f4-46a9-a539-daf44716ab59/dta1341-fig-0001-m.jpg)
Erythropoietin and erythropoiesis stimulating agents - Debeljak - 2012 - Drug Testing and Analysis - Wiley Online Library
View of Conversion from Epoetin Alfa to Darbepoetin Alfa: Effects on Patients' Hemoglobin and Costs to Canadian Dialysis Centres | Canadian Journal of Hospital Pharmacy
RESISTANCE TO RECOMBINANT HUMAN ERYTHROPOIETIN THERAPY - STUDIES IN EXPERIMENTAL MODELS OF ANEMIA AND CHRONIC KIDNEY DISEASE
![Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-013-0063-y/MediaObjects/12325_2013_63_Fig1_HTML.gif)
Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink
Switching from Epoetin Alpha to Darbepoetin Alpha in Japanese Hemodialysis Patients: Dose Conversion Ratio - FullText - Nephron Clinical Practice 2009, Vol. 111, No. 2 - Karger Publishers
![Frontiers | Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective Frontiers | Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective](https://www.frontiersin.org/files/Articles/425662/fphar-09-01498-HTML/image_m/fphar-09-01498-i001.jpg)
Frontiers | Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
View of Conversion from Epoetin Alfa to Darbepoetin Alfa: Effects on Patients' Hemoglobin and Costs to Canadian Dialysis Centres | Canadian Journal of Hospital Pharmacy
![Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease | American Society of Nephrology Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease | American Society of Nephrology](https://cjasn.asnjournals.org/content/clinjasn/13/8/1204/F1.large.jpg?download=true)